Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 9/20 | 0.41 |
| ▸ | TACR1 | P25103 | 5/20 | 0.37 |
| ▸ | TACR3 | P29371 | 4/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5815270 | 1.00 | TACR2 (0.41) | TACR2TACR1TACR3MCHR1PRCP | |
| SCHEMBL5814301 | 0.92 | TACR2 (0.50) | TACR2TACR1TACR3PRCP | |
| SCHEMBL4255036 | 0.92 | TACR2 (0.50) | TACR2TACR1TACR3PRCP | |
| SCHEMBL4258113 | 0.90 | TACR2 (0.50) | TACR2TACR1TACR3PRCP | |
| SCHEMBL5801567 | 0.90 | TACR2 (0.50) | TACR2TACR1TACR3PRCP | |
| SCHEMBL4263331 | 0.90 | TACR2 (0.48) | TACR2TACR1TACR3PRCP | |
| SCHEMBL5136246 | 0.90 | TACR2 (0.40) | TACR2TACR1TACR3 | |
| SCHEMBL4410645 | 0.89 | TACR2 (0.42) | TACR2TACR1TACR3PRCP | |
| SCHEMBL5013763 | 0.89 | TACR2 (0.41) | TACR2TACR1TACR3 | |
| SCHEMBL4259228 | 0.89 | TACR2 (0.40) | TACR2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006062478-A1 | NOVEL TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | claimed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | TACR2 19/4885TACR1 28/4885TACR3 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.